Figure 5.

Network meta-analysis for overall survival of subgroup analyses. (A) Pooled hazard ratio (HR) [95% CrIs (credible intervals)] for overall survival (OS) of squamous and non-squamous subgroups. (B) Pooled HR (95% CrIs) for OS of PD-L1 <1% and PD-L1 ≥1% subgroups. (C) Pooled HR (95% CrIs) for OS of PD-L1 1%–49% and PD-L1 ≥50% subgroups. (D) Pooled HR (95% CrIs) for OS of high TMB and low TMB subgroups. Data in each cell are HR (95% CrIs) for the comparison of upper row-defining treatment vs. lower row-defining treatment. HR less than 1 favors upper row-defining treatment. Significant results are highlighted in red and bold. SICI, single immune checkpoint inhibitor; DICI, double immune checkpoint inhibitors; SICI+CT, single immune checkpoint inhibitor combined with chemotherapy; DICI+CT, double immune checkpoint inhibitors combined with chemotherapy; CT, chemotherapy.